With the success of PD-1/PD-L1 axis blocking trials in solid tumors, immunotherapy has assumed a central position in the treatment of cancer, and many clinical trials with anti-PD-L1 monoclonal antibodies (mAbs) have been developed. This evidence concerns the gene CD274 and cancer.